Medicaid patients taking second generation anti-psychotic drugs (SGA) didn't get adequate screening for baseline serum glucose and lipids. According to research published in Archives of General Psychiatry, and based on records from California, Colorado and Missouri, in the year after FDA regulations alerted practitioners to the risks of metabolic syndrome leading to life-shortening weight gain, diabetes and cardiovascular complications, there was little change in testing rates in the year after (2004-2005) after the warnings. Analysis of medical charts before and after the FDA warnings were issued compared 204,000 people using albuterol, widely used for asthma, during the same time, with 110,000 people taking SGAs.The authors report:

"The FDA warnings and related risk communication concerning SGA drugs and risk of diabetes and dyslipidemia appear to have had no detectable effect on average baseline serum glucose or lipid testing rates for SGA-treated adults in the 3 state Medicaid populations studied. Absolute rates of baseline testing were low; on average, less than 30% of SGA-treated patients received baseline serum glucose and less than 15% received lipid testing. Rates of baseline testing did not increase following the warning."( emphasis added)

The authors suggest that rather than more testing for these conditions, there seemed to be a decline in one of the drugs, olanzapine (Zyprexa), publicly associated with this syndrome. The insufficiency of treatment for this has led to a public health crisis.